Literature DB >> 4043181

In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen.

R Löser, K Seibel, W Roos, U Eppenberger.   

Abstract

This study demonstrates in vivo and in vitro properties of the non-steroidal antiestrogens tamoxifen (TAM), 4-OH-tamoxifen (4-OH-TAM) and 3-OH-tamoxifen (K 060 E). In immature rabbit uteri 4-OH-TAM and K 060 E bound to the respective estrogen receptors with a ten-fold higher affinity than TAM. Furthermore, K 060 E exhibited less agonistic (estrogenic) but higher antagonistic (antiestrogenic) activity in the immature rat uterus than TAM and 4-OH-TAM (change of uterine weight). The ratio of agonistic vs antagonistic effect of K 060 E was distinctly lower than in TAM and 4-OH-TAM. In addition, K 060 E reduced by approximately 45% the growth of the transplantable Fisher rat mammary tumor (R 3230 AC) as compared with TAM (33%). We assume that, due to the higher antitumor activity, K 060 E (3-OH-TAM) is a better antiestrogen than TAM.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4043181     DOI: 10.1016/0277-5379(85)90119-1

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  9 in total

1.  Investigations of droloxifene and other hormonal manipulations on N-nitrosomethylurea-induced rat mammary tumours. 2. Influence on oestrogen receptor.

Authors:  M Görlich; G Winterfeld; P Hauff; W Arnold; I Fichtner; H J Staab
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 3.  Clinical pharmacology of selective estrogen receptor modulators.

Authors:  B Haynes; M Dowsett
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

4.  Biochemical and pharmacological effects of toremifene metabolites.

Authors:  L Kangas
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Effect of continuous vs intermittent application of 3-OH-tamoxifen or tamoxifen on the proliferation of the human breast cancer cell line MCF-7 M1.

Authors:  M Dietel; R Löser; P Röhlke; W Jonat; A Niendorf; D Gerding; A Kohr; F Hölzel; H Arps
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

6.  Phase I trial of droloxifene in patients with metastatic breast cancer.

Authors:  A U Buzdar; S Kau; G N Hortobagyi; R L Theriault; D Booser; F A Holmes; R Walters; I H Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Droloxifene, a new antiestrogen: its role in metastatic breast cancer.

Authors:  W Rauschning; K I Pritchard
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Tamoxifen metabolism: pharmacokinetic and in vitro study.

Authors:  M C Etienne; G Milano; J L Fischel; M Frenay; E François; J L Formento; J Gioanni; M Namer
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

9.  Binding sites of droloxifene in the cytosol of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.

Authors:  I Kawamura; E Lacey; Y Tanaka; F Nishigaki; T Manda; K Shimomura
Journal:  Jpn J Cancer Res       Date:  1994-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.